These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

428 related items for PubMed ID: 31014129

  • 1. Carrier-free combination dry powder inhaler formulation of ethionamide and moxifloxacin for treating drug-resistant tuberculosis.
    Momin MAM, Sinha S, Tucker IG, Das SC.
    Drug Dev Ind Pharm; 2019 Aug; 45(8):1321-1331. PubMed ID: 31014129
    [Abstract] [Full Text] [Related]

  • 2. Bedaquiline containing triple combination powder for inhalation to treat drug-resistant tuberculosis.
    Rangnekar B, Momin MAM, Eedara BB, Sinha S, Das SC.
    Int J Pharm; 2019 Oct 30; 570():118689. PubMed ID: 31513868
    [Abstract] [Full Text] [Related]

  • 3. Triple combination dry powder formulation of pretomanid, moxifloxacin, and pyrazinamide for treatment of multidrug-resistant tuberculosis.
    Fan C, Eedara BB, Sinha S, Uddin MKM, Doyle C, Banu S, Das SC.
    Int J Pharm; 2024 Apr 10; 654():123984. PubMed ID: 38461874
    [Abstract] [Full Text] [Related]

  • 4. Dry powder formulation of kanamycin with enhanced aerosolization efficiency for drug-resistant tuberculosis.
    Momin MAM, Sinha S, Tucker IG, Doyle C, Das SC.
    Int J Pharm; 2017 Aug 07; 528(1-2):107-117. PubMed ID: 28583333
    [Abstract] [Full Text] [Related]

  • 5. Phospholipid-based pyrazinamide spray-dried inhalable powders for treating tuberculosis.
    Eedara BB, Tucker IG, Das SC.
    Int J Pharm; 2016 Jun 15; 506(1-2):174-83. PubMed ID: 27091294
    [Abstract] [Full Text] [Related]

  • 6. L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders.
    Li L, Sun S, Parumasivam T, Denman JA, Gengenbach T, Tang P, Mao S, Chan HK.
    Eur J Pharm Biopharm; 2016 May 15; 102():132-41. PubMed ID: 26970252
    [Abstract] [Full Text] [Related]

  • 7. The influence of surface active l-leucine and 1,2-dipalmitoyl-sn-glycero-3-phosphatidylcholine (DPPC) in the improvement of aerosolization of pyrazinamide and moxifloxacin co-spray dried powders.
    Eedara BB, Rangnekar B, Doyle C, Cavallaro A, Das SC.
    Int J Pharm; 2018 May 05; 542(1-2):72-81. PubMed ID: 29524618
    [Abstract] [Full Text] [Related]

  • 8. The influence of storage relative humidity on aerosolization of co-spray dried powders of hygroscopic kanamycin with the hydrophobic drug rifampicin.
    Momin MAM, Tucker IG, Das SC.
    Drug Dev Ind Pharm; 2019 Jul 05; 45(7):1205-1213. PubMed ID: 30990097
    [Abstract] [Full Text] [Related]

  • 9. Inhalable Dry Powder of Bedaquiline for Pulmonary Tuberculosis: In Vitro Physicochemical Characterization, Antimicrobial Activity and Safety Studies.
    Momin MAM, Rangnekar B, Sinha S, Cheung CY, Cook GM, Das SC.
    Pharmaceutics; 2019 Oct 01; 11(10):. PubMed ID: 31581469
    [Abstract] [Full Text] [Related]

  • 10. Protection of hydrophobic amino acids against moisture-induced deterioration in the aerosolization performance of highly hygroscopic spray-dried powders.
    Yu J, Chan HK, Gengenbach T, Denman JA.
    Eur J Pharm Biopharm; 2017 Oct 01; 119():224-234. PubMed ID: 28655664
    [Abstract] [Full Text] [Related]

  • 11. Physicochemical stability and aerosolization performance of dry powder inhalation system containing ciprofloxacin hydrochloride.
    Karimi K, Katona G, Csóka I, Ambrus R.
    J Pharm Biomed Anal; 2018 Jan 30; 148():73-79. PubMed ID: 28965047
    [Abstract] [Full Text] [Related]

  • 12. Influence of excipients on physical and aerosolization stability of spray dried high-dose powder formulations for inhalation.
    Shetty N, Park H, Zemlyanov D, Mangal S, Bhujbal S, Zhou QT.
    Int J Pharm; 2018 Jun 10; 544(1):222-234. PubMed ID: 29678544
    [Abstract] [Full Text] [Related]

  • 13. Nano spray-dried pyrazinamide-L-leucine dry powders, physical properties and feasibility used as dry powder aerosols.
    Kaewjan K, Srichana T.
    Pharm Dev Technol; 2016 Jun 10; 21(1):68-75. PubMed ID: 25331092
    [Abstract] [Full Text] [Related]

  • 14. Manipulation of spray-drying conditions to develop dry powder particles with surfaces enriched in hydrophobic material to achieve high aerosolization of a hygroscopic drug.
    Momin MAM, Tucker IG, Doyle CS, Denman JA, Das SC.
    Int J Pharm; 2018 May 30; 543(1-2):318-327. PubMed ID: 29626509
    [Abstract] [Full Text] [Related]

  • 15. Powder, capsule and device: An imperative ménage à trois for respirable dry powders.
    Schoubben A, Blasi P, Giontella A, Giovagnoli S, Ricci M.
    Int J Pharm; 2015 Oct 15; 494(1):40-8. PubMed ID: 26255220
    [Abstract] [Full Text] [Related]

  • 16. Co-spray drying of hygroscopic kanamycin with the hydrophobic drug rifampicin to improve the aerosolization of kanamycin powder for treating respiratory infections.
    Momin MAM, Tucker IG, Doyle CS, Denman JA, Sinha S, Das SC.
    Int J Pharm; 2018 Apr 25; 541(1-2):26-36. PubMed ID: 29458207
    [Abstract] [Full Text] [Related]

  • 17. Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.
    Lin Y, Chang RYK, Britton WJ, Morales S, Kutter E, Li J, Chan HK.
    Eur J Pharm Biopharm; 2019 Sep 25; 142():543-552. PubMed ID: 31398437
    [Abstract] [Full Text] [Related]

  • 18. Investigation of the Changes in Aerosolization Behavior Between the Jet-Milled and Spray-Dried Colistin Powders Through Surface Energy Characterization.
    Jong T, Li J, Morton DA, Zhou QT, Larson I.
    J Pharm Sci; 2016 Mar 25; 105(3):1156-63. PubMed ID: 26886330
    [Abstract] [Full Text] [Related]

  • 19. Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance.
    Son YJ, Worth Longest P, Hindle M.
    Int J Pharm; 2013 Feb 25; 443(1-2):137-45. PubMed ID: 23313343
    [Abstract] [Full Text] [Related]

  • 20. Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells.
    Aquino RP, Prota L, Auriemma G, Santoro A, Mencherini T, Colombo G, Russo P.
    Int J Pharm; 2012 Apr 15; 426(1-2):100-107. PubMed ID: 22301426
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.